Context The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the
treatment of many urologic cancers. Objective To provide a contemporary picture of the risks …

The ability of cancer cells to evade the immune system is one of the most deadly
characteristics of the majority of malignant tumours. Accordingly, the recent development of …

Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

Prostate cancer is the most frequent cancer in men and a leading cause of cancer death.
Determining a patient's optimal therapy is a challenge, where oncologists must select a …

Background Androgen deprivation therapy (ADT) with radiotherapy can benefit patients with
localized prostate cancer. However, ADT can negatively impact quality of life, and there …

Background Randomised trials have investigated various androgen deprivation therapy
(ADT) intensification strategies in men receiving radiotherapy for the treatment of prostate …

As the global COVID-19 pandemic escalates there is a need within radiation oncology to
work to support our patients in the best way possible. Measures are required to reduce …

Background The indirect impact of the COVID-19 pandemic on cancer outcomes is of
increasing concern. However, the extent to which key treatment modalities have been …

Purpose During a global pandemic, the benefit of routine visits and treatment of patients with
cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is …

Purpose: The summary presented herein represents Part III of the three-part series
dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing …